Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Sleep apnea pill developer gets $150M as U.S. filing nears
Apnimed, a pharmaceutical company, has secured up to $150 million in debt financing from HealthCare Royalty Partners. This funding will support the commercial launch of AD109, an oral pill for obstructive sleep apnea (OSA), pending FDA approval. The company plans to submit a New Drug Application (NDA) for AD109 later this quarter, following positive Phase 3 trial results.